SSR3 (Signal Sequence Receptor Subunit 3)

This review emphasizes the crucial roles of the TRAP complex and its subunits (SSR1-SSR4) in various diseases, highlighting their potential as therapeutic targets and biomarkers. Future research should focus on understanding the mechanisms through integrated experimental and multi-omics approaches, defining subunit interactions, and exploring structure-based drug design for clinical applications.

Our study established a novel MRI-proteomics integration framework for NAC response prediction, with MRI defining spatial resistance patterns and proteomics deciphering molecular drivers, enabling early organ preservation strategies. The zero-imputation design ensured deplorability in diverse clinical settings.

Plasma cells are key clusters in HCC development. A prognostic model based on the PCRGs can accurately predict the prognosis of patients with HCC and guide clinical treatment.

SSR1 was overexpressed in LIHC and is associated with poor prognosis. It plays a critical role in promoting LIHC cell proliferation and survival, suggesting its potential as a diagnostic marker and therapeutic target.

P1/2, N=57, Recruiting, Northwestern University

Our study identifies SSR3 as a potential oncogene in humans, implicated in both tumorigenesis and cancer immunity. Elevated SSR3 expression is indicative of an immunosuppressive tumor microenvironment. Therefore, SSR3 holds promise as a potential prognostic biomarker and a target for immunotherapy in cancer treatment.